



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|--|-------------|----------------------|------------------------------------|------------------------|
| 10/597,173 | 07/13/2006 | Cheol-Min Kim | P10031US | 7115 |
| 58986 7590 03/19/2008 THE RAFFERTY PATENT LAW FIRM 5641 BURKE CENTRE PKWY SUITE 100 BURKE, VA 22015-2259 | | | EXAMINER OGUNBIYI, OLUWATOSIN A | |
| | | | ART UNIT 1645 | PAPER NUMBER |
| | | | MAIL DATE 03/19/2008 | DELIVERY MODE PAPER |

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/597,173

Applicant(s)

KIM ET AL.

Examiner

OLUWATOSIN OGUNBIYI

Art Unit

1645

Period for Reply -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 2/18/08.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-9 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-9 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/55/08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

Claims 1-9 are pending in the application.

Upon further consideration of the claims, the restriction requirement mailed 1/18/2008 is withdrawn, in favor of a new restriction requirement as set forth below.

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

- Group I, claim(s) 1, drawn to oligonucleotides for genus-specific genotyping of *Mycoplasma* and *Ureaplasma* strains.
- Group I, claim(s) 2, drawn to oligonucleotides for species-specific genotyping of *Mycoplasma* and *Ureaplasma* strains.
- Group III, claim(s) 3, drawn to oligonucleotides for genus-specific genotyping *Acholeplasma* strains.

Art Unit: 1645

- Group IV, claim(s) 4, drawn to oligonucleotides for species-specific genotyping *Acholeplasma* strains.
- Group V, claims 5-7 and 9 drawn to a microarray comprising more than one oligonucleotide selected from genus-specific and species-specific oligonucleotides for genotyping *Mycoplasma* and *Ureaplasma* and *Acholeplasma* strains and a kit comprising more than one oligonucleotide selected from genus-specific and species-specific oligonucleotides for genotyping *Mycoplasma* and *Ureaplasma* and *Acholeplasma* strains.
- Group VI, claim(s) 8, drawn to a method for detecting *Mycoplasma* strains.

The inventions listed as Groups I -VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The technical feature linking Group I-V is an oligonucleotide.

Groups I lacks unity with Group II -V, because the technical feature of the Groups is anticipated by the art and therefore not "special" within the meaning of PCT Rule 13.2 because it does not provide for a contribution that the claimed invention makes over the art. The first appearing technical feature is an oligonucleotide comprising

SEQ ID NO:7. This technical feature is anticipated by Harasawa et al. J. Vet. Med. Sci. 58(3):191-195, 1996. Harasawa et al teach an oligonucleotide that comprises a sequence that is 100 % identical to SEQ ID NO: 7 (see attached sequence alignment).

Notice of Possible Rejoinder

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the

above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Species Election

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1. The species are as follows:

Group I - Oligonucleotide for genus-specific typing of *Mycoplasma* and *Ureaplasma*: SEQ ID Nos. 7-21.

Group II - Oligonucleotide for species-specific typing of *Mycoplasma* and *Ureaplasma*: SEQ ID Nos. 28-127

Group III - Oligonucleotide for genus-specific typing of *Acholeplasma*: SEQ ID Nos. 22-27

Art Unit: 1645

Group IV - Oligonucleotide for species-specific typing of *Acholeplasma*: SEQ ID Nos. 128-133.

Group V

A. (1) Oligonucleotide for genus-specific and species-species oligonucleotide for typing of *Mycoplasma* and *Ureaplasma* : SEQ ID Nos. 7-21 and SEQ ID NO: 28 to 127 (2) Oligonucleotide for genus-specific and species-species oligonucleotide typing of *Acholeplasma* : SEQ ID Nos. 22-27 and SEQ ID NO: 128 to 133.

B. Probes: DNA,RNA,PNA,LNA and HNA.

C. Support: slide glass, plastic, membrane, semiconductive chip, silicon and gel.

Group VI

A. Oligonucleotide for genus-specific and species-species oligonucleotide typing of *Mycoplasma* and *Ureaplasma* : SEQ ID Nos. 7-21 and SEQ ID NO: 28 to 127

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: technical feature linking species is not novel and is not defined over the prior art (Harasawa et al as set forth supra).

Applicant is required, in reply to this action, to elect a single species from each category of species listed for the Group of invention elected and to which the claims shall be restricted if no generic claim is finally held to be allowable.

- If any of Groups I-IV is elected, Applicant is directed to elect a single sequence from the sequences listed under each Group.
- If Group V is elected, Applicant is directed to elect a combination of species from each of A-C. For example, elect and define the more than one (the combination) genus-specific and species-species oligonucleotide for typing of *Mycoplasma* and *Ureaplasma* from any of SEQ ID Nos. 7-21 and SEQ ID NO: 28 to 127 in addition to a single probe and a single support. Or, elect and define the more than one (the combination) genus-specific and species-species oligonucleotide for typing of *Acholeplasma* selected from any of SEQ ID Nos. 22-27 and SEQ ID NO: 128 to 133 in addition to a single probe and single support.
- If Group VI is elected, Applicant is directed to elect and define the more than one (the combination) oligonucleotides for genus-specific and species-species oligonucleotide for typing of *Mycoplasma* and *Ureaplasma* : SEQ ID Nos. 7-21 and SEQ ID NO: 28 to 127 that are used as probes.

Currently, there are no generic claim(s). The reply must also identify the claims readable on the elected species, including any claims subsequently added. An

argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

If a generic claim(s) is added and upon the allowance of the generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Oluwatosin Ogunbiyi whose telephone number is 571-272-9939. The examiner can normally be reached on M-F 8:30am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shanon Foley can be reached on 571-272-0898. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Art Unit: 1645

If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Oluwatosin Ogunbiyi/

Examiner, Art Unit 1645

/Patricia A. Duffy/

Primary Examiner, Art Unit 1645